Table 2 Tumor response of the intention-to-treat population according to treatment arm

From: First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort IKF-AIO-MOONLIGHT trial

 

Arm A/A1 N = 90

Arm A2

N = 60

Arm B

N = 60

Arm C

N = 52

Complete response

6 (7%)

6 (10%)

3 (5%)

5 (10%)

Partial response

35 (39%)

13 (22%)

25 (42%)

24 (46%)

Stable disease

29 (32%)

26 (43%)

14 (23%)

16 (31%)

Progressive disease

11 (12%)

8 (13%)

12 (10%)

3 (6%)

Missing

9 (10%)

7 (12%)

6 (10%)

4 (8%)

Objective response rate

[95% CI]

46% [35%,56%]

32%

[20%,45%]

47%

[34%,60%]

56%

[41%,70%]

Disease control rate

78%

75%

70%

87%

Median duration of response

[95% CI]

6.2 months [4.0;8.8]

4.3 months [1.9;8.7]

5.4 months [4.0;9.0]

8.8 months [5.3; 12.6]

Median duration of stabilization

[95% CI]

4.9 months

[3.8;7.7]

3.5 months [2.0;5.2]

6.9 months [4.8;9.0]

5.7 months

[3.4;8.1]